Mrs Claire Cantley
- Affiliate -Clinical Trials Unit (School of Cancer Sciences)
email:
Claire.Cantley@glasgow.ac.uk
Coap, Alexander Stone Building, Alexander Stone Building
The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Clarity helps us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
email:
Claire.Cantley@glasgow.ac.uk
Coap, Alexander Stone Building, Alexander Stone Building
Fleming, L., Randell, K., Stewart, E., Espie, C. A., Morrison, D. S., Lawless, C. and Paul, J. (2019) Insomnia in breast cancer: a prospective observational study. Sleep, 42(3), zsy245. (doi: 10.1093/sleep/zsy245) (PMID:30521041)
Hatton, M. Q.F. et al. (2019) Accelerated, dose escalated, sequential chemoradiotherapy in non-small-cell lung cancer (ADSCaN): a protocol for a randomised phase II study. BMJ Open, 9(1), e019903. (doi: 10.1136/bmjopen-2017-019903) (PMID:30700475) (PMCID:PMC6352760)
Stewart, G. D. et al. (2017) Cytoreductive nephrectomy in the tyrosine kinase inhibitor era: a question that may never be answered. European Urology, 71(6), pp. 845-847. (doi: 10.1016/j.eururo.2016.10.029) (PMID:27815086)
Fleming, L., Randell, K., Stewart, E., Espie, C. A., Morrison, D. S., Lawless, C. and Paul, J. (2019) Insomnia in breast cancer: a prospective observational study. Sleep, 42(3), zsy245. (doi: 10.1093/sleep/zsy245) (PMID:30521041)
Hatton, M. Q.F. et al. (2019) Accelerated, dose escalated, sequential chemoradiotherapy in non-small-cell lung cancer (ADSCaN): a protocol for a randomised phase II study. BMJ Open, 9(1), e019903. (doi: 10.1136/bmjopen-2017-019903) (PMID:30700475) (PMCID:PMC6352760)
Stewart, G. D. et al. (2017) Cytoreductive nephrectomy in the tyrosine kinase inhibitor era: a question that may never be answered. European Urology, 71(6), pp. 845-847. (doi: 10.1016/j.eururo.2016.10.029) (PMID:27815086)